Evidence map›Paper›PMID 40045045›Full record

ArticleFamilial cancer2025

Addressing uncertainty in hereditary colorectal cancer: the role of a regional expert multidisciplinary team meeting.

Avani Varde, Terri McVeigh, Vicky Cuthill, Angela F Brady, Bianca DeSouza, Andrew Latchford, Kevin J Monahan

Abstract read
In one paragraph

Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Outcomes of 'in-house' genetic testing within a specialist hereditary colorectal cancer registry.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Avani VardeThe Centre for Familial Intestinal Cancer, St Mark's The National Bowel Hospital, Acton Lane, Park Royal, London, NW10 7NS, UK.
Terri McVeighThe Royal Marsden Hospital, London, UK.
Vicky CuthillThe Centre for Familial Intestinal Cancer, St Mark's The National Bowel Hospital, Acton Lane, Park Royal, London, NW10 7NS, UK.
Angela F BradyNorth West Thames Regional Genetics Service, London, UK.
Bianca DeSouzaNorth West Thames Regional Genetics Service, London, UK.
Andrew LatchfordThe Centre for Familial Intestinal Cancer, St Mark's The National Bowel Hospital, Acton Lane, Park Royal, London, NW10 7NS, UK.
Kevin J MonahanThe Centre for Familial Intestinal Cancer, St Mark's The National Bowel Hospital, Acton Lane, Park Royal, London, NW10 7NS, UK. k.monahan@imperial.ac.uk.ORCID 0000-0002-7918-4003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is frequent uncertainty in both the precise quantification of risk, and the application of clinical interventions, designed to mitigate increased heritable colorectal cancer (CRC) susceptibility. We evaluated the role of a collaborative specialist multidisciplinary team meeting (MDM) for familial and hereditary CRC, led by the St Mark's Hospital Centre for Familial Intestinal Cancer specifically in supporting the clinical management of uncertainty. A retrospective thematic analysis of meeting outcomes from inception in June 2020 until March 2023 was performed. Descriptive statistics were employed to ascertain clinicopathological data, clinical queries and whether MDM recommendations were outside the scope of current guidelines. In total 260 cases were discussed from 13 regional institutions. A prior personal history of cancer was present in 215 (82.6%), and a family history of CRC in 107(41.2%) and non-CRC 27(10.4%) cases. In thematic analysis uncertainty related to indications for genetic testing was considered in 148 (56.9%) of cases, with unexplained mismatch repair deficiency (u-dMMR) in 78 (30%) of cases, and resolution of molecular interpretation in 61 (23.5%). Surveillance related queries represented 55 (21.1%), and mainstreaming 29 (11%) of cases. Management was recommended beyond the scope of existing guidelines in 64 (24.6%) cases. This regional hereditary CRC MDM provides clinicians with support in areas of uncertainty in diagnosis and clinical management, supporting clinical decision-making where evidence and clinical guidelines may be limited. This model could be replicated to support complexity in clinical care in other geographical regions or other health conditions.

Indexed as

Colorectal NeoplasmsPatient Care TeamAdultAgedFemaleGenetic Predisposition to DiseaseGenetic TestingHumansMaleMiddle AgedRetrospective StudiesUncertaintyGenetic testingHereditary colorectal cancerMainstreamingMultidisciplinary collaboration

Identifiers

PMID40045045
PMCPMC11882607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.